Assessment of selected markers of apoptosis and angiogenesis in chronic lymphocytic leukemia

Czech version

Authors: M. Motyčková ¹; L. Smolej ¹; C. Andrýs ²; V. Řezáčová ²; V. Řeháček ³; M. Šimkovič ¹; D. Belada ¹; P. Žák ¹
Authors‘ workplace: IV. interní hematologická klinika Lékařské fakulty a FN Hradec Králové, přednosta doc. MU Dr. Pavel Žák, Ph. D. ¹; Ústav klinické imunologie a alergologie Lékařské fakulty UK a FN Hradec Králové, přednosta prof. RNDr. Jan Krejsek, CSc. ²; Transfuzní oddělení Lékařské fakulty UK a FN Hradec Králové, přednosta prim. MU Dr. Vít Řeháček ³
Published in: Vnitř Lék 2013; 59(9): 782-793
Category: Original Contributions

Overview

Introduction:
Search for new prognostic markers in order to improve prognostic accuracy and predict clinical outcome at the time of diagnosis has recently become one of the major trends in chronic lymphocytic leukemia (CLL).

Patients and methods, aim of study:
The aim of our study was assessment of selected markers of apoptosis and angiogenesis and their potential as new prognostic factors. We evaluated serum levels of tumor necrosis factor α (TNF‑α) and transforming growth factor β‑ 1 (TGF‑β1) using comercially available enzyme‑linked immunosorbent assay; furthemore, we quantified expression of type II receptor for transforming growth factor beta (TGFβRII) and type 2 receptor for fibroblast growth factor‑ 2 (FGFR2) on CLL cells using flow cytometry analysis in 75 previously untreated patients with CLL (47 males and 28 females, median age, 65 years, range 38– 82) and healthy donors.

Results:
We found significantly elevated TNF‑α in patients with CLL compared to the control group (p < 0.0001); high expression of TNF‑α was associated with unfavourable prognosis: significantly higher concentrations were found in patients with Rai high‑risk group compared to low and intermediate-risk group (p = 0.0008 and p = 0.0097), with high serum β₂- microglobulin (p = 0.045), massive lymphadenopathy (p = 0.0083), unmutated genes for variable region of immunoglobulin heavy chain (IgVH) (p = 0.041) and unfavourable cytogenetic aberrations (p = 0.0014). In addition, patients with progressive CLL had significantly higher TNF‑α than those with stable clinical course (p = 0.0009); time to treatment was significantly shorter in patients with higher TNF‑α (p = 0.0049). Higher TGF‑β1 concentrations were associated with favourable subgroups: with Rai low‑ risk group compared to high‑risk group (p = 0.011), patients without massive lymphadenopathy (p = 0.041), patients with mutated IgVH (p = 0.012) and ZAP‑ 70 negativity (zeta‑associated protein of 70 kilodaltons) (p = 0.044). Patients with progressive CLL had significantly lower TGF‑β1 levels than those with stable course (p = 0.0014) and time to treatment was significantly longer in patients with higher TGF‑β1 (p = 0.016). Patients with Rai high‑risk group had significantly lower TGFβRII expression than those with low‑ risk group (p = 0.022). The prognostic significance of FGFR2 was not found. Significant and independent prognostic factors for overall survival were high serum concentrations of TNF‑α and massive lymphadenopathy (p = 0.036, resp. p = 0.047).

Conclusion:
Based on our results, TNF‑α and TGF‑β1 possess prognostic significance in CLL; further research in this direction may also be important therapeutically, because these signal pathways could serve as possible treatment targets.

Key words:
chronic lymphocytic leukemia – prognosis – TNF‑α – TGF‑β1 – TGFβRII – FGFR2 – apoptosis – angiogenesis

Sources

1. Vroblová V, Smolej L, Vrbacký F et al. Biological prognostic markers in chronic lymphocytic leukemia. Acta Medica (Hradec Kralove) 2009; 52: 3– 8.

2. Zanioni A, Imperiali FG, Pasquini C et al. Cytokine modulation of nuclear factor‑ kB activity in B‑ chronic lymphocytic leukemia. Exp Hematol 2003; 31: 185– 190.

3. Meinhardt G, Wendtner CM, Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med (Berl) 1999; 77: 282– 293.

4. Gerondakis S, Strasser A. The role of Rel/ NF‑ kappaB transcription factors in B lymphocyte survival. Semin Immunol 2003; 15: 159– 166.

5. Digel W, Porzsolt F, Schmid M et al. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type Bchronic lymphocytic leukemia. J Clin Invest 1992; 89: 1690– 1693.

6. Rosati E, Sabatini R, Tabilio A et al. B‑ chronic lymphocytic leukemia cells exert an in vitro cytotoxicity mediated by tumor necrosis factor alpha. Leuk Res 2005; 29: 829– 839.

7. Ferrajoli A, Keating MJ, Manshouri T et al. The clinical significance of tumor necrosis factor‑alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002; 100: 1215– 1219.

8. Kast RE, Altschuler EL. Anti‑apoptosis function of TNF‑alpha in chronic lymphocytic leukemia: lessons from Crohnʼs disease and the therapeutic potential of bupropion to lower TNF‑alpha. Arch Immunol Ther Exp (Warsz) 2005; 53: 143– 147.

9. Trentin L, Zambello R, Agostini C et al. Expression and regulation of tumor necrosis factor, interleukin‑2, and hematopoietic growth factor receptors in B‑ cell chronic lymphocytic leukemia. Blood 1994; 84: 4249– 4256.

10. Cheson BD. Chronic lymphoid leukemias: Second Edition, revised and Expanded. New York: Marcel Dekker, Inc. 2001: 118– 141.

11. Waage A, Espevik T. TNF receptors in chronic lymphocytic leukemia. Leuk Lymphoma 1994; 13: 41– 46.

12. Munzert G, Kirchner D, Stobbe H et al. Tumor necrosis factor receptor‑associated factor 1 gene overexpression in B‑ cell chronic lymphocytic leukemia: analysis of NF‑ kappa B/ Rel‑ regulated inhibitors of apoptosis. Blood 2002; 100: 3749– 3756.

13. Bojarska‑ Junak A, Hus I, Szczepanek E et al. Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B‑ CLL in correlation with ZAP‑ 70 protein and CD38 antigen. Leuk Res 2008; 32: 225– 233.

14. Singer M, Assem M, Abdel AB et al. Role of TNF‑alpha as a survival prognostic marker in chronic lymphocytic leukemia patients. Egypt J Immunol 2011; 18: 51– 60.

15. Lech‑ Maranda E, Grzybowska‑ Izydorczyk O, Wyka K et al. Serum tumor necrosis factor‑alpha and interleukin‑10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status. Arch Immunol Ther Exp (Warsz) 2012; 60: 477– 486.

16. Huang SS, Huang JS. TGF‑beta control of cell proliferation. J Cell Biochem 2005; 96: 447– 462.

17. Dong M, Blobe GC. Role of transforming growth factor‑beta in hematologic malignancies. Blood 2006; 107: 4589– 4596.

18. Buske C, Becker D, Feuring‑ Buske M et al. TGF‑beta and its receptor complex in leukemic B‑ cell precursors. Exp Hematol 1998; 26: 1155– 1161.

19. von Bergwelt‑ Baildon M, Maecker B, Schultze J et al. CD40 activation: potential for specific immunotherapy in B‑ CLL. Ann Oncol 2004; 15: 853– 857.

20. Fuchs O. Úloha signální dráhy indukované transformačním růstovým faktorem beta při vzniku nádoru. Klin Onkol 2002; 15: 7– 16.

21. Pertovaara L, Kaipainen A, Mustonen T et al. Vascular endothelial growth factor is induced in response to transforming growth factor‑beta in fibroblastic and epithelial cells. J Biol Chem 1994; 269: 6271– 6274.

22. Friedenberg WR, Salzman SA, Phan SM et al. Transforming growth factor‑beta and multidrug resistance in chronic lymphocytic leukemia. Med Oncol 1999; 16: 110– 118.

23. Gora‑ Tybor J, Blonski JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators Inflamm 2003; 12: 167– 171.

24. Ho CL, Phyliky RL, Li CY. B‑ cell chronic lymphocytic leukemia: correlation of clinical stages with angiogenic cytokine expression. Appl Immunohistochem Mol Morphol 2006; 14: 154– 160.

25. DeCoteau JF, Knaus PI, Yankelev H et al. Loss of functional cell surface transforming growth factor beta (TGF‑beta) type 1 receptor correlates with insensitivity to TGF‑beta in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 5877– 5881.

26. Lagneaux L, Delforge A, Bron D et al. Heterogenous response of B lymphocytes to transforming growth factor‑beta in B‑ cell chronic lymphocytic leukaemia: correlation with the expression of TGF‑beta receptors. Br J Haematol 1997; 97: 612– 620.

27. Schiemann WP, Rotzer D, Pfeifer WM et al.Transforming growth factor‑beta (TGF‑beta)‑resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF‑beta receptor. Cancer Detect Prev 2004; 28: 57– 64.

28. R Romano S, Mallardo M, Chiurazzi F et al. The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells. Haematologica 2008; 93: 1039– 1048.

29. Lagneaux L, Delforge A, Bernier M et al. TGF‑beta activity and expression of its receptors in B‑ cell chronic lymphocytic leukemia. Leuk Lymphoma 1998; 31: 99– 106.

30. Okada‑ Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor‑ 2. Int J Biochem Cell Biol 2000; 32: 263– 267.

31. Baguma‑ Nibasheka M, Li AW, Osman MSet al. Coexpression and regulation of the FGF‑ 2 and FGF antisense genes in leukemic cells. Leuk Res 2005; 29: 423– 433.

32. Bairey O, Zimra Y, Shaklai M et al. Bcl‑ 2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 113: 400– 406.

33. Smolej L, Benešová P. Význam angiogeneze u maligních nádorů. Acta Medica Suppl 2005; 48: 69– 72.

34. Smolej L, Andrýs C, Maisnar V et al. Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica (Hradec Kralove) 2005; 48: 57– 58.

35. Gora‑ Tybor J, Blonski JZ, Robak T. Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia. Neoplasma 2002; 49: 145– 148.

36. Smolej L, Andrýs C, Krejsek J et al. Bazický fibroblastový růstový faktor (bFGF) a cévní endotelový růstový faktor (VEGF) jsou zvýšeny v plazmě periferní krve nemocných s chronickou lymfocytární leukemií a klesají po intenzivní léčbě obsahující fludarabin. Vnitř Lék 2007; 53: 1171– 1176.

37. Molica S, Vitelli G, Levato D et al. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B‑ cell chronic lymphocytic leukaemia. Br J Cancer 2002; 86: 31– 35.

38. Molica S, Cutrona G, Vitelli G et al. Markers of increased angiogenesis and their correlation with biological parameters identifying high‑risk patients in early B‑ cell chronic lymphocytic leukemia. Leuk Res 2007; 31: 1575– 1578.

39. Bairey O, Boycov O, Kaganovsky E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B‑ chronic lymphocytic leukemia (CLL) cells. Leuk Res 2004; 28: 243– 248.

40. Gora‑ Tybor J, Blonski JZ, Robak T. Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. Eur Cytokine Netw 2005; 16: 41– 46.

41. Allouche M, Bayard F, Clamens S et al. Expression of basic fibroblast growth factor (bFGF) and FGF‑ receptors in human leukemic cells. Leukemia 1995; 9: 77– 86.

42. Krejci P, Dvorakova D, Krahulcova E et al. FGF‑ 2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. Leukemia 2001; 15: 228– 237.

43. König A, Menzel T, Lynen S et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl‑ 2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997; 11: 258– 265.

44. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute‑ Working Group 1996 guidelines. Blood 2008; 111: 5446– 5456.

45. Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR (eds). Chronic Lymphocytic Leukemia. Recent Progress and Future Direction. New York: AR Liss 1987.

46. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910– 1916.

47. Bockstaele VF, Verhasselt B, Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009; 23: 25– 47.

48. Montillo M, Hamblin T, Hallek M et al. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk‑adapted therapeutic strategies. Haematologica 2005; 90: 391– 399.

49. Motyčková M, Žák P, Vroblová V et al. Prognostické faktory u chronické lymfocytární leukemie. Vnitř Lék 2011; 57: 847– 857.

50. Malčíková J, Pospíšilová Š, Mayer J et al. Význam nádorového supresoru p53 u chronické lymfocytární leukemie. Transfuze Hematol Dnes 2010; 16: 29– 32.

51. Kozák T. Prognostické faktory chronické lymfocytátní leukemie. Transfuze Hematol Dnes 2010; 16: 56– 61.

52. Hamblin TJ. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007; 20: 455– 468.

53. Hallek M, Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 2011; 25: 1– 9.

54. Gentile M, Mauro FR, Guarini A et al. New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. Curr Opin Oncol 2005; 17: 597– 604.

55. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22: 211– 219.

56. Osorio LM, Jondal M, Aguilar‑ Santelises M. Regulation of B‑ CLL apoptosis through membrane receptors and Bcl‑ 2 family proteins. Leuk Lymphoma 1998; 30: 247– 256.

57. Novosad J, Kodydková K, Krejsek J. Apoptóza, její mechanizmy a medicínský význam. II. Poruchy regulace apoptózy a jejich souvislost s rozvojem onemocnění. Vnitř Lék 2001; 47: 387– 390.

58. Gentile M, Cutrona G, Neri A et al. Predictive value of beta2- microglobulin (beta2-m)levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 2009; 94: 887– 888.

59. Douglas RS, Capocasale RJ, Lamb RJ et al. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor‑beta. Blood 1997; 89: 941– 947.

60. Lagneaux L, Delforge A, Dorval C et al. Excessive production of transforming growth factor‑beta by bone marrow stromal cells in B‑ cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin‑6 production. Blood 1993; 82: 2379– 2385.

61. Norin S, Kimby E, Lundin J. Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia. Med Oncol 2010; 27: 820– 825.

62. Smolej L, Bachh A, Vodárek P et al. The role of imaging methods in chronic lymphocytic leukemia: significant internal lymphadenopathy is frequent and associated with shorter overall survival. Haematologica 2012; 97: 302.

63. Eichhorst BF, Fischer K, Fink AM et al. Limited clinical relevance of imaging techniques in the follow‑up of patients with advanced chronic lymphocytic leukemia: results of a meta‑analysis. Blood 2011; 117: 1817– 1821.

64. Sorror ML, Storer BE, Sandmaier BM et al. Five‑year follow‑up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26: 4912– 4920.

65. Horiuchi T, Mitoma H, Harashima S et al. Transmembrane TNF‑alpha: structure, function and interaction with anti‑TNF agents. Rheumatology 2010; 49: 1215– 1228.

66. Pour L, Hájek R, Buchler T et al. Angiogeneze a antiangiogenní terapie u nádorů. Vnitř Lék 2004; 50: 930– 938.

Labels

Diabetology Endocrinology Internal medicine

Does physical activity produce clinically significant changes during discontinuation of insulin pump in type 1 diabetic patients?

Use of natriuretic peptides in diagnosis of left ventricular hypertrophy in obese hypertensive patients with metabolic syndrome

The importance of cardiac biomarker assay for the stratification and monitoring of AL amyloidosis patients – single center experience

Compliance of senior/ elderly patients with cognitive impairment

RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the non‑intervention RESOLUTE Project in the Czech Republic

Food intake regulation – 1st part

Recommendation of the Czech society of Endocrinology for the treatment of Cushing’s syndrome in adults

Cold agglutinin disease – no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature

Regional migrating osteoporosis – a case report

Article was published in

Internal Medicine

2013 Issue 9